Stem cells for heart failure
Friday, 06 June, 2008
Mesoblast (ASX: MSB) will soon launch phase II trials into congestive heart failure, the company said.
The trials will be conducted by its US-based sister company Angioblast Systems.
The US FDA recently granted the companies permission to perform clinical trials using its adult stem cell-based treatment.
45 clients suffering from congestive heart failure will be given allogeneic stem cells, while 15 will be given a placebo.
The stem cells will be injected directly into the patients' hearts through a cardiac catheter.
In pilot trials conducted in Australia, a similar injection method using the patients' own cells was shown to improve heart muscle function and reduce the risk of heart failure. Mesoblast said using healthy stem cells will improve the results even further.
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
